CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A

Cell Reports

Volumn 15, Issue 11, 2016, Pages 2340-2347

  Chu, Jennifer ^a   Galicia Vázquez, Gabriela ^a   Cencic, Regina ^a   Mills, John R ^a,d   Katigbak, Alexandra ^a   Porco, John A ^c   Pelletier, Jerry ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c USA   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Chemical biology; CRISPR Cas9; EIF4A; Rocaglates; Translational control

Indexed keywords

CASPASE 9; CRISPR ASSOCIATED PROTEIN; INITIATION FACTOR 4A; BENZOFURAN DERIVATIVE; SILVESTROL; TRITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENE LOCUS; GENETIC COMPLEMENTATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN RNA BINDING; RNA EDITING; TRANSLATION INITIATION; ALLELE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CRISPR CAS SYSTEM; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; MUTATION; NIH 3T3 CELL LINE; NUCLEOTIDE SEQUENCE; NUDE MOUSE; REPRODUCIBILITY;

ALLELES; ANIMALS; BASE SEQUENCE; BENZOFURANS; CRISPR-CAS SYSTEMS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE; EUKARYOTIC INITIATION FACTOR-4A; FEMALE; GENETIC LOCI; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; NIH 3T3 CELLS; REPRODUCIBILITY OF RESULTS; TRITERPENES;

EID: 84969765688     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.05.005     Document Type: Article

References (26)

1. Bhat M., Robichaud N., Hulea L., Sonenberg N., Pelletier J., Topisirovic I. Targeting the translation machinery in cancer. Nat. Rev. Drug Discov. 2015, 14:261-278.
2. Bordeleau M.E., Robert F., Gerard B., Lindqvist L., Chen S.M., Wendel H.G., Brem B., Greger H., Lowe S.W., Porco J.A., Pelletier J. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J. Clin. Invest. 2008, 118:2651-2660.
3. Cencic R., Carrier M., Galicia-Vázquez G., Bordeleau M.E., Sukarieh R., Bourdeau A., Brem B., Teodoro J.G., Greger H., Tremblay M.L., et al. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS ONE 2009, 4:e5223.
4. Chu J., Cencic R., Wang W., Porco J.A., Pelletier J. Translation Inhibition by Rocaglates Is Independent of eIF4E Phosphorylation Status. Mol. Cancer Ther. 2016, 15:136-141.
5. Elfakess R., Sinvani H., Haimov O., Svitkin Y., Sonenberg N., Dikstein R. Unique translation initiation of mRNAs-containing TISU element. Nucleic Acids Res. 2011, 39:7598-7609.
6. Elliott B., Richardson C., Winderbaum J., Nickoloff J.A., Jasin M. Gene conversion tracts from double-strand break repair in mammalian cells. Mol. Cell. Biol. 1998, 18:93-101.
7. Galicia-Vázquez G., Cencic R., Robert F., Agenor A.Q., Pelletier J. A cellular response linking eIF4AI activity to eIF4AII transcription. RNA 2012, 18:1373-1384.
8. Graff J.R., Konicek B.W., Vincent T.M., Lynch R.L., Monteith D., Weir S.N., Schwier P., Capen A., Goode R.L., Dowless M.S., et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J. Clin. Invest. 2007, 117:2638-2648.
9. Hong D.S., Kurzrock R., Oh Y., Wheler J., Naing A., Brail L., Callies S., André V., Kadam S.K., Nasir A., et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin. Cancer Res. 2011, 17:6582-6591.
10. Jafari R., Almqvist H., Axelsson H., Ignatushchenko M., Lundbäck T., Nordlund P., Martinez Molina D. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat. Protoc. 2014, 9:2100-2122.
11. Leibiger C., Kosyakova N., Mkrtchyan H., Glei M., Trifonov V., Liehr T. First molecular cytogenetic high resolution characterization of the NIH 3T3 cell line by murine multicolor banding. J. Histochem. Cytochem. 2013, 61:306-312.
12. Lin C.J., Nasr Z., Premsrirut P.K., Porco J.A., Hippo Y., Lowe S.W., Pelletier J. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Rep. 2012, 1:325-333.
13. Lorsch J.R., Herschlag D. The DEAD box protein eIF4A. 1. A minimal kinetic and thermodynamic framework reveals coupled binding of RNA and nucleotide. Biochemistry 1998, 37:2180-2193.
14. Niesen F.H., Berglund H., Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2007, 2:2212-2221.
15. Pan L., Woodard J.L., Lucas D.M., Fuchs J.R., Kinghorn A.D. Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species. Nat. Prod. Rep. 2014, 31:924-939.
16. Polier G., Neumann J., Thuaud F., Ribeiro N., Gelhaus C., Schmidt H., Giaisi M., Köhler R., Müller W.W., Proksch P., et al. The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2. Chem. Biol. 2012, 19:1093-1104.
17. Rajalingam K., Wunder C., Brinkmann V., Churin Y., Hekman M., Sievers C., Rapp U.R., Rudel T. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat. Cell Biol. 2005, 7:837-843.
18. Robert F., Roman W., Bramoullé A., Fellmann C., Roulston A., Shustik C., Porco J.A., Shore G.C., Sebag M., Pelletier J. Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma. Proc. Natl. Acad. Sci. USA 2014, 111:13421-13426.
19. Rodrigo C.M., Cencic R., Roche S.P., Pelletier J., Porco J.A. Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies. J. Med. Chem. 2012, 55:558-562.
20. Rubio C.A., Weisburd B., Holderfield M., Arias C., Fang E., DeRisi J.L., Fanidi A. Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation. Genome Biol. 2014, 15:476.
21. Sadlish H., Galicia-Vazquez G., Paris C.G., Aust T., Bhullar B., Chang L., Helliwell S.B., Hoepfner D., Knapp B., Riedl R., et al. Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex. ACS Chem. Biol. 2013, 8:1519-1527.
22. Smurnyy Y., Cai M., Wu H., McWhinnie E., Tallarico J.A., Yang Y., Feng Y. DNA sequencing and CRISPR-Cas9 gene editing for target validation in mammalian cells. Nat. Chem. Biol. 2014, 10:623-625.
23. Truitt M.L., Conn C.S., Shi Z., Pang X., Tokuyasu T., Coady A.M., Seo Y., Barna M., Ruggero D. Differential requirements for eIF4E dose in normal development and cancer. Cell 2015, 162:59-71.
24. Wolfe A.L., Singh K., Zhong Y., Drewe P., Rajasekhar V.K., Sanghvi V.R., Mavrakis K.J., Jiang M., Roderick J.E., Van der Meulen J., et al. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature 2014, 513:65-70.
25. Yang L., Guell M., Byrne S., Yang J.L., De Los Angeles A., Mali P., Aach J., Kim-Kiselak C., Briggs A.W., Rios X., et al. Optimization of scarless human stem cell genome editing. Nucleic Acids Res. 2013, 41:9049-9061.
26. Yoder-Hill J., Pause A., Sonenberg N., Merrick W.C. The p46 subunit of eukaryotic initiation factor (eIF)-4F exchanges with eIF-4A. J. Biol. Chem. 1993, 268:5566-5573.